IRIS
AMADORI, SERGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 83.818
EU - Europa 7.438
AS - Asia 3.266
SA - Sud America 55
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 16
AF - Africa 13
Totale 94.627
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 83.765
DE - Germania 2.698
SG - Singapore 1.429
UA - Ucraina 1.215
CN - Cina 1.209
IE - Irlanda 719
IT - Italia 677
RU - Federazione Russa 634
GB - Regno Unito 495
KR - Corea 369
FI - Finlandia 268
SE - Svezia 254
FR - Francia 230
PL - Polonia 81
NL - Olanda 45
JP - Giappone 42
CA - Canada 38
IN - India 34
UZ - Uzbekistan 31
BE - Belgio 27
BR - Brasile 24
ID - Indonesia 20
AT - Austria 18
PH - Filippine 18
ES - Italia 16
CL - Cile 15
VN - Vietnam 15
TR - Turchia 14
AU - Australia 13
EU - Europa 13
IR - Iran 13
CH - Svizzera 12
CZ - Repubblica Ceca 12
HK - Hong Kong 11
MX - Messico 9
PE - Perù 8
TW - Taiwan 8
EG - Egitto 7
GR - Grecia 7
PK - Pakistan 7
PT - Portogallo 7
A2 - ???statistics.table.value.countryCode.A2??? 6
IL - Israele 6
AR - Argentina 5
DK - Danimarca 5
IQ - Iraq 5
KG - Kirghizistan 5
MY - Malesia 5
NO - Norvegia 5
SA - Arabia Saudita 5
DM - Dominica 4
LT - Lituania 4
CO - Colombia 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
MA - Marocco 3
RO - Romania 3
A1 - Anonimo 2
AL - Albania 2
BH - Bahrain 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
QA - Qatar 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CR - Costa Rica 1
FJ - Figi 1
KW - Kuwait 1
KZ - Kazakistan 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
Totale 94.627
Salva come PNG Salva come JPEG
Città #
Woodbridge 27.051
Wilmington 22.140
Houston 18.980
Fairfield 2.518
Ann Arbor 2.131
Chandler 1.371
Singapore 1.235
Ashburn 1.229
Jacksonville 1.123
Seattle 1.064
Cambridge 848
Dearborn 766
Dublin 699
Medford 550
Beijing 450
New York 306
Zhengzhou 300
Santa Clara 297
Lawrence 258
Rome 192
Mülheim 158
San Diego 120
Moscow 95
Menlo Park 87
Milan 72
Boardman 71
Kraków 68
Shanghai 68
Falls Church 64
Creede 55
Hefei 55
Redwood City 51
Nanjing 50
Norwalk 49
University Park 48
London 45
Mountain View 43
Munich 40
San Mateo 37
Kunming 36
Guangzhou 34
Palo Alto 32
Nürnberg 31
Los Angeles 30
Verona 30
Helsinki 26
Saint Petersburg 25
Bologna 24
Hangzhou 24
Brussels 23
Nanchang 17
Toronto 17
Florence 16
Kilburn 16
Phoenix 15
Shenyang 15
Jakarta 14
Jinan 14
Nuremberg 14
Auburn Hills 13
Seongnam 13
Seoul 13
Center 12
Groningen 12
Hebei 12
Turin 12
Chicago 11
Detroit 11
Dong Ket 11
San Francisco 11
Brno 10
Manila 10
Fuzhou 9
Hounslow 9
Indiana 9
Redmond 9
Lima 8
Pune 8
Chiswick 7
Council Bluffs 7
Frankfurt am Main 7
Innsbruck 7
São Paulo 7
Brescia 6
Chengdu 6
Madrid 6
Mumbai 6
Quzhou 6
Tokyo 6
Vienna 6
Washington 6
Wuhan 6
Acton 5
Amsterdam 5
Chaoyang 5
Diyarbakır 5
Leawood 5
Louisville 5
Montreal 5
Naples 5
Totale 85.569
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 609
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 555
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 480
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 479
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 477
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 475
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 473
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 469
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 461
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 456
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 455
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 452
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 452
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 451
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia 449
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 448
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 446
6-phosphogluconate dehydrogenase deficiency in an Italian family 445
Treatment of multiple myeloma: A randomized study of three different regimens 444
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 444
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study 443
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 440
Acute foetal distress and umbilical cord blood banking 439
Clinical significance of CD38 expression in chronic lymphocytic leukemia 437
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study 436
Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent 435
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 435
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 435
Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura 434
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 432
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice 432
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 430
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 430
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 430
Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators 430
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 429
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 429
High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant 428
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 426
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 426
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 426
Placental/Umbilical cord blood: experience of St. Eugenio Hospital collection center 425
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 425
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 424
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia 421
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 421
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 421
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 421
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 420
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 418
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 417
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 416
Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes 415
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 415
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 415
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 415
Biological features of acute myeloid leukemia in the elderly 415
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 415
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia 414
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults 414
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 414
Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab 413
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab 412
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 412
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 412
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience 411
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 411
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 411
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 411
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 411
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 411
null 410
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. 408
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 408
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study 407
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 406
A new system for quality control in hematopoietic progenitor cell units before reinfusion in autologous transplant. 406
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 405
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 405
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 405
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 405
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 405
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 404
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial 403
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients 402
AML-M0: a biological and clinical profile 402
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. 400
Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: A long-term follow-up study 398
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review 398
Induction of Apoptosis by Pyrrolobenzothiadiazepines (PBTDs) in cell lines and in 12 chronic myeloid leukaemia patients and imatinib-resistant 398
Unrelated Cord Blood transplantaion for children with high risk myelodysplastic syndrome 398
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 398
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 396
Gemtuzumab ozogamicin (Mylotarg((R))) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups 394
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 392
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation 391
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 391
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. 390
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 390
FISH analysis for CML monitoring? 388
Totale 42.581
Salva come PNG Salva come JPEG
Categoria #
all - tutte 174.459
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 174.459
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202013.857 0 0 0 0 0 2.695 2.236 2.100 1.971 1.872 1.368 1.615
2020/202113.333 1.556 1.603 1.377 1.782 1.351 1.386 1.672 1.232 354 288 555 177
2021/20222.559 91 290 104 124 72 251 135 132 142 262 150 806
2022/20233.622 404 252 210 410 282 762 338 212 400 31 244 77
2023/20241.219 141 41 62 29 146 408 87 45 15 20 23 202
2024/20252.748 214 1.383 681 304 96 70 0 0 0 0 0 0
Totale 95.093